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Background. Healthcare cost and reforms are at the forefront of international debates. One of the current
discussion themes in oncology is whether and how patients’ life changes due to costs of cancer care. In
Norway, the main part of the treatment costs is supported by general taxpayer revenues.
Objectives. The objective of this study was to clarify whether head and neck cancer patients (n67) in
northern Norway experienced financial health-related quality of life (HRQOL) deterioration due to costs
associated with treatment.
Design. HRQOL was examined by the European Organization for Research and Treatment of Cancer
(EORTC) QLQ-C30 in the beginning and in the end of radiation treatment in patients treated at the University
Hospital in Northern Norway. Changes in financial HRQOL were calculated and compared by paired sample
T-tests. Multiple regression analyses were used to examine correlations among gender, marital status, age and treat-
ment with or without additional chemotherapy and changes in the HRQOL domain of financial difficulties.
Results. The majority of score results at both time points were in the lower range (mean 1525), indicating
limited financial difficulties. We observed no statistically significant differences by gender, marital status and
age. Increasing financial difficulties during treatment were reported by male patients and those younger than
65, that is, patients who were younger than retirement age. The largest effect was seen in singles. However,
differences were not statistically significant.
Conclusions. During the initial phase of the disease trajectory, no significant increase in financial difficulties was
found. This is in line with the aims of the Norwegian public healthcare model. However, long-term longitudinal
studies should be performed, especially with regard to the trends we observed in single, male and younger patients.
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C
ancer is one of the world’s major diseases, a
burden on patients and their families. Among
others, cancer can have direct and indirect
financial implications for patients and/or their families.
Head and neck cancer (HNC) is the sixth most common
malignancy globally, and poses a substantial economic
burden to healthcare systems (1). In North America and
Europe, approximately 50% of HNC patients are treated
with surgery, and a combination of treatment modalities
including concurrent radiotherapy and chemotherapy (2).
The past decade has seen substantial changes in the
treatment of HNC, with more widespread application of
advancements such as robotic surgery and intensity-
modulated radiotherapy (IMRT). These measures reduce
treatment-related toxicity and morbidity (1). However,
they may contribute to additional costs for the patients,
dependent on healthcare system and insurance status.
A significant amount of rehabilitation and supportive
therapies are required to maintain or restore patients’
normal organ function and activities of daily living (2).
Multidisciplinary rehabilitation might include nutritional
support, dietary counselling, swallowing and speech
therapy (1). These treatments have the ability to improve
patients’ health-related quality of life (HRQOL) (3).
Previous studies have mainly focused on the costs that
are driven by complex pathways and the need for
involvement of several medical specialties (1). Few
reports described costs associated with treatment-related
side effects and follow-up care. Wissinger et al. evaluated
77 studies, mostly conducted in the USA, and found that
costs are higher for HNC patients with recurrent and/or
metastatic disease for patients undergoing surgery and
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patients insured by private payers (1). Many patients
receiving cancer treatment experience both a financial
burden and subjective financial distress (4). Most studies
were performed in the USA, where publicly funded
healthcare is limited, health insurance is linked to
employment and patients may have high medical care
costs (57). A small number of studies have focused on
medical costs in countries with greater concentration of
public-funded healthcare, such as the UK and Canada.
These studies showed lower costs for patients (8,9). In
Ireland, which has a mixed publicprivate healthcare
system, cancer patients who were working at diagnosis
experienced a drop of income, and cancer diagnoses in
general caused variable amounts of out-of-pocket ex-
penses (10). The authors of this study concluded that a
complex mixed publicprivate healthcare system does not
always provide adequate financial protection post-cancer.
The healthcare system in Norway is based on general
taxpayer revenues. This means that Norwegian citizens do
not pay for health insurance and have equal access to
healthcare. Norwegians have to pay a small out-of-pocket
amount for drugs, each medical examination or treatment.
The government has set a maximum annual amount
for these co-payments. The patients do not need to pay
for travel cost, parking, accommodation (outpatient
going through radiation treatment long way from home)
or devices such as wheelchairs. The Norwegian social
security system covers patients’ loss of income and their
family members can apply for reimbursement of lost
earnings. With this national public healthcare system,
the government expects that patients should not experi-
ence related economic consequences. In other words,
financial burden of cancer therapy should be absent or
minimal. This study sought to examine HNC patients’
financial HRQOL during curative radiation treatment
and evaluate changes regarding financial difficulties in the
initial phase of treatment.
Methods
Study design and patient sample
This prospective study was conducted at the University
Hospital in Northern Norway from May 2009 to
November 2012. Sixty-seven HNC patients participated
and the main results have been published earlier (11). The
study was approved by the Regional Committee for
Medical Research Ethics (P REK NORD 200900504-
3KST017/400) and the Norwegian Social Science Data
Services (21831).
Data collection
Socio-demographic and tumour-related patient charac-
teristics were recorded at inclusion, that is, age, gender,
marital status, tumour location according to ICD-10,
TNM stage (Ttumour size, Nnodal metastases,
Mdistant metastases) and planned treatment was
registered.
Data were collected at 2 time points: at baseline which
was the first week of radiation treatment, and during the
last week after administration of 60 Gy. The patients
filled in the European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30 (12) and
EORTC QLQ-H&N35 questionnaires (13). The EORTC
QLQ-C30 questionnaire is a generic questionnaire for all
cancers. The questionnaire is a patient-based measure-
ment designed for self-administration which assesses
multiple dimensions of HRQOL, and responses of this
30-item questionnaire are categorized into 5 functional
domains (physical, role, emotional, cognitive and social)
scored on a 4-point scale, one global HRQOL domain
(scored on a 7-point scale), 3 symptom domains (fatigue,
nausea/vomiting, pain) and 6 single items (dyspnoea,
insomnia, appetite loss, constipation, diarrhoea, financial
difficulties, scored on a 4-point scale). The financial
question to the patients was: has your physical condition
or medical treatment caused you financial difficulties?
The patients could answer: not at all, a little, quite a bit or
very much.
Each score was transformed into 0100 point scale.
Both EORTC instruments were scored according to
recommendations in the EORTC QLQ-C30 scoring
manual (14). In the 5 functional scales and the global
HRQOL scale, a high score represents a high level of
functioning or global HRQOL. In the symptom scales
and single items, a higher score implies a high level of
symptoms or problems. Regarding financial difficulties,
the answer ‘‘not at all’’ corresponded to 0 points, ‘‘a
little’’ to 33.33 points, ‘‘quite a bit’’ to 66.66 points and
‘‘very much’’ to 100 points. EORTC QLQ-H&N35 is a
questionnaire specifically developed for HNC patients
consisting of 35 items on health-related HRQOL.
Clinical treatment
Post-operative or definitive radiotherapy was administered
to the primary tumour and the regional neck lymphatics
(dependent on N stage) by conventional fractionation, that
is, daily dose of 2 Gy, 5 days per week. The total radiation
doseswere in the range of 6070 Gy delivered over a period of
67 weeks. All patients were treated with three-dimensional
conformal or IMRT (Table I).
Statistical analysis
In the present study, the primary outcome of interest was
to examine early financial burden. Relevant information
from baseline questionnaires was available in 64 patients.
Changes in HRQOL were calculated and compared by
paired sample T-tests. Multiple regression analyses were
used to examine if baseline characteristics had any
influence on changes in HRQOL. The significance level
was set at p0.05 using the statistical software SPSS
21.0 for Windows.
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Results
The baseline characteristics of the patients are presented
in Table I. The mean age was 60, and 49 male and 18
female patients were included in the study. Forty-nine per
cent were married and 28% were single. Dividing the
tumour locations into 5 groups (oral cavity, pharynx,
larynx, salivary glands and others), the most common
sites of primary tumours were the oral cavity, followed by
pharynx and larynx. With regard to the T-stage, 60% had
T1 and T2 tumours. A minority (42%) had no lymph
node metastases (N0). During the treatment period, most
item scores in the EORTC-C30 declined significantly,
except for emotional functional status and social func-
tional status in female patients (Table II). In the single
item questions, there were significant changes in dys-
pnoea, appetite and constipation during the treatment
period (details not shown).
As shown in Table III, 57 patients (89%) provided end-
of-treatment data about financial difficulty. The majority
of score results at both time points were in the lower
range (mean 1525), indicating limited financial diffi-
culty. We observed no statistically significant differences
by gender, marital status and age. Combined chemor-
adiotherapy (n24), which is more aggressive and toxic
compared to radiotherapy alone, was not associated with
increasing financial difficulties. The following trends
emerged: increasing financial difficulties during treatment
in male patients (n48) and those aged under 65, that is,
patients who were younger than retirement age (n43).
The largest effect was seen in singles (n16). However,
the differences did not reach the level of statistical
significance.
Discussion
This study mainly evaluated changes in financial HRQOL
and examined if age, marital status, gender and chemother-
apy modified these changes during radiation treatment in
a population of HNC patients. Validated general HRQOL
questionnaires were used (15,16), which also formed the
basis of previous Norwegian studies in cancer patients
(17,18). Bentzen et al. reported on patients previously
treated for anal cancer and a comparison group of
volunteers (18). Regarding financial difficulties, the mean
score was 4 in volunteers and 14 in cancer survivors,
pB0.001. The results for volunteers were in line with other
European data, which might serve as reference values
(mean scores 510, average 5.7) (19).
Our patients reported that most aspects of non-financial
HRQOL declined significantly during the radiation treat-
ment period, a finding which is in accordance with other
studies (17,2024). Financial difficulty did not change
significantly in the treatment period. The majority of score
results at both time points (start/end of radiotherapy)
were in the lower range (mean 1525), indicating limited
financial difficulties. However, based on reference values
even lower scores could have been expected. We observed
no statistically significant differences by gender, marital
status and age. However, increasing financial difficulties
during treatment emerged in male patients and those
younger than 65, that is, patients who were younger than
retirement age. The largest effect was seen in the small
subgroup of singles. However, statistical significance was
not achieved when comparing subgroups. It appears
understandable that singles are more vulnerable to finan-
cial problems than couples because they only have one
income. In Norway, usually both partners are working,
and in our study population we can expect that many
patients were working at diagnosis because the mean age
was 60. The social security system in Norway pays full
salary from the first day the patients are unable to work
and the patients and families have access to compensatory
payments such as sick pay for spouse or social welfare
assistance.





Mean (min, max) 60 (2184)
Gender
Male, n (%) 49 (73.1)




Missing information 15 (22.4)
Tumour location
Oral cavity, n (%) 17 (25.4)
Pharynx, n (%) 16 (23.9)
Larynx, n (%) 16 (23.9)
Salivary glands, n (%) 7 (10.4)
Others/unknown, n (%) 11 (16.4)
T-stage (tumour size)
T1, n (%) 21 (31.4)
T2, n (%) 20 (29.9)
T3, n (%) 8 (11.9)
T4, n (%) 8 (11.9)
Tx, n (%) 10 (14.9)
N stage (lymph nodes)
N0, n (%) 28 (41.8)
N1, n (%) 17 (25.4)
N2, n (%) 11 (16.4)
Nx, n (%) 10 (16.4)
IMRT (intensity-modulated radiotherapy)
Yes, n (%) 13 (19.4)
Chemotherapy
Yes, n (%) 24 (35.8)
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Financial burden of cancer therapy is a hot topic in
many countries. Irrespective of healthcare system, re-
sources are limited and threatened by increasing costs of
treatment. Often, at least a proportion of costs are incurred
by the patients, potentially compromising their family
economy, savings and future plans. The Norwegian system
aims at minimizing individual responsibility for cost of
medical care and resulting consequences (25,26). Norway
has the highest per capita healthcare cost of all the Nordic
countries (27). These countries are similar demographi-
cally and politically, and have comparable welfare and
healthcare institutions (25). The financial and economic
impact of cancer is influenced by the healthcare and social
welfare setting (10). We expect the same result in northern
Norway as in the south of Norway because the Norwegian
population has identical economic welfare. Studies from
other countries illustrated the negative impact of finan-
cial burden. Wong et al. reported on a total of 400 US-
American cancer patients who reviewed 2 of 3 stylized
curative and non-curative scenarios that asked them to
choose between 2 treatments of varying levels of efficacy,
toxicity and cost (28). Each scenario included 9 choice sets.
Demographics, cost concerns, numeracy and optimism
were assessed. The median age of the patients was 61.
Ninety-nine per cent of patients were insured. Three latent
classes were identified that demonstrated (a) preference for
Table II. Changes in quality of life (EORTC-C30) from baseline to end of treatment in women and men
EORTC QLQ-C30 Baseline mean; SD End mean; SD Mean difference; SD p
Physical men (n) 82.8; 17.2 (48) 68.2; 24.6 (44) 15.9; 20.2 (43) 0.000
Physical women (n) 83.3; 14.0 (16) 63.3; 25.7 (14) 20.6; 21.2 (12) 0.003
p p 0.913 p 0.518 p 0.491
Role men (n) 73.6; 27.5 (48) 48.3; 34.6 (40) 26.5; 31.7 (39) 0.000
Role women (n) 63.5; 28.0 (16) 28.6; 30.3 (14) 43.1; 20.7 (12) 0.000
p p 0.211 p 0.063 p 0.096
Emotional men (n) 84.3; 19.1 (48) 74.4; 24.0 (44) 10.1; 27.6 (43) 0.021
Emotional women (n) 71.9; 27.5 (16) 75.6; 23.4 (14) 1.4; 24.1 (12) 0.538
p p 0.050 p 0.873 p 0.195
Cognitive men (n) 86.8; 19.4 (48) 74.1; 26.5 (44) 13.4; 23.2 (43) 0.000
Cognitive women (n) 83.3; 21.1 (16) 64.3; 37.5 (14) 20.8; 31.9 (12) 0.026
p p 0.547 p 0.284 p 0.370
Social men (n) 73.6; 27.3 (48) 62.7; 31.0 (42) 10.6; 20.3 (41) 0.002
Social women (n) 61.5; 32.6 (16) 48.8; 37.2 (14) 20.8; 46.1 (12) 0.221
p p 0.147 p 0.173 p 0.269
Global health men (n) 67.7; 20.4 (48) 48.3; 25.8 (44) 20.3; 20.3 (43) 0.000
Global health women (n) 60.9; 30.1 (16) 45.2; 24.8 (14) 22.9; 29.5 (12) 0.012
p p 0.314 p 0.001 p 0.728
Table III. Changes in quality of life (EORTC-C30) from baseline to end of treatment: financial difficulty
EORTC QLQ-C30 Baseline mean; SD End mean; SD Mean difference; SD p
Financial difficulty
Men 18.1; 30.7 (48) 25.0; 32.2 (44) 6.2; 31.9 0.210
Women 25.0; 33.3 (16) 15.4; 22.0 (13) 6.1; 20.1 0.190
p p 0.446 p 0.319 p 0.232
Age B65 years 19.4; 30.2 (43) 24.8; 31.3 (39) 3.7; 24.9 0.520
Age ]65 years 20.6; 34.1 (21) 18.5; 28.5 (18) 3.7; 39.4 0.695
p p 0.882 p 0.473 p 1.000
Single 22.9; 33.8 (16) 33.3; 37.0 (14) 12.8; 34.8 0.209
Married 22.2; 31.1 (33) 20.7; 27.3 (29) 1.2; 31.3 1.000
p p 0.782 p 0.213 p 0.297
Cisplatin and RT 20.8; 36.5 (24) 19.3; 30.1 (19) 1.9; 38.7 1.000
RT alone 17.2; 27.0 (31) 23.0: 29.7 (29) 4.9; 22.1 0.255
p p 0.674 p 0.677 p 0.735
Note that not all patients provided end-of-treatment data.
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survival, (b) aversion to high cost and (c) aversion to
toxicity. Across all scenarios, patients with higher income
were more likely to be in the class that favoured survival.
Lower income patients were more likely to be in the class
that was averse to high cost (pB0.05). Zafar et al.
conducted baseline and follow-up surveys regarding the
impact of healthcare costs on well-being and treatment
among US-American cancer patients who contacted a
national co-payment assistance foundation along with a
comparison sample of patients treated at an academic
medical centre (4). Among 254 participants, 75% applied
for drug co-payment assistance. Forty-two per cent of
participants reported a significant or catastrophic sub-
jective financial burden; 68% cut back on leisure activities,
46% reduced spending on food and clothing and 46% used
savings to defray out-of-pocket expenses. To save money,
20% took less than the prescribed amount of medication,
19% partially filled prescriptions and 24% avoided filling
prescriptions altogether. In an adjusted analysis, younger
age, larger household size, applying for co-payment
assistance and communicating with physicians about costs
were associated with greater subjective financial burden.
In contrast, Norwegian cancer patients are expected to
experience much less financial consequences after diag-
nosis. At first sight, our results confirm this hypothesis.
When interpreting our findings, the limitations of this
study have to be acknowledged. The patient numbers
and statistical power were limited and not all patients
provided end-of-treatment data (89%). No detailed in-
formation about different aspects of personal economy
was collected. Time elapsed from cancer diagnosis to
end of treatment was limited (approximately 34 months,
depending on whether surgical resection was performed
before radiotherapy). Therefore, we were only able to
evaluate the initial phase of the disease trajectory. Another
Norwegian study assessed the impact of breast cancer on
survivors’ annual income at 113 years of follow-up (29).
The dataset contained casecontrol pairs, where each
pair consisted of one breast cancer case and a cancer-
free control, matched for age, marital status and munici-
pality of residence. The income of breast cancer survivors
had reduced immediately following diagnosis. At 1 year
after diagnosis, income development between cases
and controls became significantly different (p0.006).
Differences increased slightly and remained significant
throughout the follow-up period. The income develop-
ment of stage I breast cancer patients was similar to their
controls. For higher stage breast cancer patients, the
income differences were more pronounced but not always
statistically significant. Ghaderi et al. analyzed long-term
medical consequences of cancer at a young age (B25
years), obtained from Norwegian social security benefit
records (30). Among the 5-year cancer survivors (4,031
individuals), 30% received social security benefits. The
survivors had an overall 4.4 times higher risk of social
security benefit uptake than the cancer-free population.
The most notified causes of social security benefit uptake
were diseases of the nervous system, and injury and
poisoning. Taken together, several sources of information
suggest that even the Norwegian health and welfare system
does not guarantee absence of financial difficulties after
cancer treatment. In order to rule out relevant differences
in HNC patients from our region and inform healthcare
authorities, larger longitudinal studies with longer follow-
up are warranted.
Conclusions
No significant financial burden was found in HNC
patients who underwent radiotherapy. This is in line
with the aims of the Norwegian public healthcare model.
However, long-term longitudinal studies should be per-
formed, especially with regard to the trends we observed
in single, male and younger patients.
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